13th week of 2014 patent applcation highlights part 41 |
Patent application number | Title | Published |
20140086807 | PIPETTE FOR USE WITH A PIPETTE TIP - A pipette ( | 2014-03-27 |
20140086808 | SPECIMEN TRANSPORT APPARATUS, SPECIMEN PROCESSING APPARATUS, AND SPECIMEN TRANSPORT METHOD - A specimen transport apparatus according to an aspect is provided with a holder which holds a cup-like specimen container accommodating a specimen in an upright position, a chain member disposed along a predetermined transport path, and a supporting portion provided in a predetermined position on the chain member and configured to support the holder. | 2014-03-27 |
20140086809 | DUAL VESSEL REACTOR - A dual vessel reactor and a method of carrying out a reaction using a dual vessel reactor are provided using a non-condensable gas to substantially isolate the inner vessel from the outer vessel during the reaction and limit the heating of the outer vessel when steam from the inner vessel condenses on the interior surface of the outer vessel. By limiting the heating of the outer vessel through the condensation of the steam or other vapour from the inner vessel, the operating temperature of the outer vessel is kept below an upper threshold of the operating temperature of a seal used to seal the door in the outer vessel. | 2014-03-27 |
20140086810 | SYSTEM AND METHOD FOR EMPLOYING CATALYTIC REACTOR COATINGS - A system includes a catalytic reactor configured to mount to a combustor. The catalytic reactor includes a catalyst configured to reduce emissions associated with combustion in the combustor. The catalytic reactor also includes a first sacrificial coating disposed over the catalyst prior to mounting of the catalytic reactor into the combustor, wherein the first sacrificial coating is removable while the catalytic reactor is mounted to the combustor without damaging the catalyst. | 2014-03-27 |
20140086811 | CARBON DIOXIDE RECOVERING APPARATUS AND METHOD FOR OPERATING THE SAME - According to one embodiment, a carbon dioxide recovering apparatus includes a flow distributor dividing the first rich solution discharged from an absorbing tower into a second rich solution and a third rich solution, a reheat exchanger heating the second rich solution with a lean solution discharged from a releasing tower as a heat source, a heating unit heating the third rich solution with a carbon dioxide containing steam to be released from the releasing tower as a heat source, a gas-liquid separator separating the carbon dioxide containing steam used to heat the third rich solution into carbon dioxide and condensate water, a measuring unit measuring an amount of the condensate water in the gas-liquid separator, and a controller. The controller controls a flow dividing ratio in the flow distributor based on a change in the amount of the condensate water measured by the measuring unit. | 2014-03-27 |
20140086812 | Sulfur Recovery Process - A process for removing sulfur compounds, particularly hydrogen sulfide, from a waste gas wherein sulfur dioxide is introduced into the process gas at multiple process locations. Quantities of sulfur dioxide are introduced into the process gas stream at one or more locations preceding catalytic reaction. The process of the present invention may be practiced for Claus processes involving initial thermal reactions, and may be practiced without necessity of preliminary thermal reaction. In an embodiment of the invention, one of the injection locations of sulfur dioxide is the thermal reactor. | 2014-03-27 |
20140086813 | PROCESS AND PLANT FOR THE REMOVAL OF NITROGEN OXIDES FROM OXYGEN-CONTAINING GAS STREAMS - The invention relates to a process for the removal of NO and NO | 2014-03-27 |
20140086814 | Production of Li2MSiO4 electrode materials in amine solvent - A process for the production of Li | 2014-03-27 |
20140086815 | USE OF SILICON CARBIDE TUBES WITH A FLANGED OR FLARED END - The invention relates to the use of a ceramic tube composed of silicon carbide variants in processes for converting chlorosilanes, wherein the tube has a flange or a flare at one end and is closed at the other end. | 2014-03-27 |
20140086816 | USE OF BURNERS WITH A JET TUBE IN REACTORS FOR CONVERSION OF CHLOROSILANES - The invention provides for the use of a particular burner design to heat reactors for conversion of chlorosilanes, wherein the burner has a jet tube and the jet tube surrounds the flame and the flame tube in a gastight manner, as a result of which the combustion air, the gaseous and/or liquid fuels, and also the flue gases cannot get into the reaction furnace space. The advantage is the complete separation of the flue gas from the actual interior of the reaction furnace, which prevents critical interactions between flue gas moisture and chlorosilanes in the case of fracture of the arrangement accommodating the chlorosilanes. This in turn makes it possible to use gaseous or liquid fuels to heat such a reaction furnace. Excessive local input of heat as a result of direct flame contact is prevented; the heat input is homogenized. | 2014-03-27 |
20140086817 | ADSORBENT GRANULATE AND METHOD FOR THE MANUFACTURE THEREOF - The invention relates to a X-zeolite based adsorbent granulate with faujasite structure and a molar SiO | 2014-03-27 |
20140086818 | Synthesis Gas Separation and Reforming Process - A method of obtaining purified hydrogen and purified carbon monoxide from crude synthesis gas. A first crude synthesis gas stream is passed through a first separation zone to separate a hydrogen stream from a stream comprising carbon monoxide and methane. The carbon monoxide and methane are subjected to thermal reforming to produce a second crude synthesis gas, which is passed through a second separation zone to separate carbon monoxide from the second crude synthesis gas stream. | 2014-03-27 |
20140086819 | POLYANILINE-GRAPHITE NANOPLATELET MATERIALS - Nanocomposite adsorbent materials and methods for their preparation and use are described. As an example, a polyaniline-graphite nanoplatelet nanocomposite may be used to adsorb carbon dioxide. | 2014-03-27 |
20140086820 | PRODUCTION METHOD AND PRODUCTION DEVICE OF NANOCARBON - Using a device for producing nanocarbon, a fluidized bed is formed by supplying a low hydrocarbon and oxygen to a fluid catalyst | 2014-03-27 |
20140086821 | CHLORINE DIOXIDE GENERATOR - A chlorine dioxide generator includes a container body deformable in response to application of a force from the outside. The container body contains therein a solid acidic composition and an aqueous chlorite solution under a non-contact state from each other. The solid acidic composition comprises a porous material containing an acidic substance. The aqueous chlorite solution is sealed within an easily breakable enclosure. In operation, when the container body is deformed, the enclosure contained therein is broken to bring the aqueous chlorite solution into contact with the solid acidic composition, whereby chlorine dioxide gas is generated. This generated chlorine dioxide gas is discharged via a gas discharge port to the outside of the container body. | 2014-03-27 |
20140086822 | CHLORINE DIOXIDE GENERATION SYSTEMS AND METHODS - Chlorine dioxide generation systems and methods are disclosed. In some embodiments, an optical analyzer may be positioned along a reactant feed line to measure a reactant concentration. A controller may adjust a flow rate of the reactant in response to information provided by the optical analyzer. | 2014-03-27 |
20140086823 | CATALYST FOR DECOMPOSITION OF SULFUR TRIOXIDE AND HYDROGEN PRODUCTION PROCESS - A sulfur trioxide decomposition catalyst, in particular, a sulfur trioxide decomposition catalyst capable of lowering the temperature required when producing hydrogen by an S—I cycle process is disclosed. A sulfur trioxide decomposition catalyst that includes a composite oxide of tungsten, vanadium and at least one metal selected from the group consisting of transition metal and rare earth elements is provided. Also, a sulfur dioxide production process that includes decomposing sulfur trioxide into sulfur dioxide and oxygen by using the sulfur trioxide decomposition catalyst above is provided. Furthermore, a hydrogen production process, wherein the reaction of decomposing sulfur trioxide into sulfur dioxide and oxygen by an S—I cycle process is performed by the above-described sulfur dioxide production process is provided. | 2014-03-27 |
20140086824 | ULTRATHIN MAGNESIUM NANOBLADES - A nanostructure includes a plurality of metal nanoblades positioned with one edge on a substrate. Each of the plurality of metal nanoblades has a large surface area to mass ratio and a width smaller than a length. A method of storing hydrogen includes coating a plurality of magnesium nanoblades with a hydrogen storage catalyst and storing hydrogen by chemically forming magnesium hydride with the plurality of magnesium nanoblades. | 2014-03-27 |
20140086825 | METHODS AND KITS FOR ASSESSING, MODULATING AND TREATING SUBSTANCES AFFECTING BODILY PROCESSES - Methods, systems, kits and devices for assessing and providing for homeostasis of signaling molecules in an individual via assessing, modulating and treating levels of modulators are provided. | 2014-03-27 |
20140086826 | SIN3B COMPLEX INHIBITION FOR PREVENTING HEMATOLOGIC CHEMOTHERAPY- AND RADIOTHERAPY-INDUCED CYTOTOXICITY - Methods for inactivating Sin3B and its associated activities to prevent, inhibit or attenuate hematopoietic stem cell exhaustion and chemotherapy- and radiotherapy-induced hematologic cytotoxicity are provided. | 2014-03-27 |
20140086827 | Serum S100B And Uses Thereof - The invention is directed to a method of assessing blood brain barrier permeability in an individual comprising selectively or specifically detecting a level of S 100BB homodimer in a sample of the individual, and comparing the level of S 100BB homodimer in the sample to a level of S 100B a control. The invention is also directed to methods of determining the effectiveness of a treatment for a neurological disorder wherein blood-brain barrier permeability is present in an individual in need thereof comprising detecting a level of S100B in a sample of the individual undergoing the treatment, and comparing the level of S 100B in the sample to the level of S100B in a sample from the individual obtained prior to treatment. The invention is also directed to a method of detecting a history of blood brain barrier disruption in an individual in need thereof comprising detecting auto | 2014-03-27 |
20140086828 | MODIFIED GOLD NANOPARTICLES FOR THERAPY - The present invention concerns methods and compositions utilizing gold nanoparticles for therapy for a medical condition, such as cancer. In particular aspects, the nanoparticles are included with or in a T cell to facilitate targeting of the nanoparticles to a desired location in vivo and/or to facilitate therapeutic treatment for the condition. In specific cases, the nanoparticle/T cell compositions further comprise microRNAs and/or peptides, and so forth. | 2014-03-27 |
20140086829 | Recombinant Antibodies to the Vascular Endothelial Growth Factor (VEGF) which are Obtained by Means of Mutagenesis of Variable Regions - The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with to an increase in vasculature, such as age-related macular degeneration, cancer, and others. | 2014-03-27 |
20140086830 | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) - The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer. | 2014-03-27 |
20140086831 | Single Wall Nanotube Constructs and Uses Thereof - The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs. | 2014-03-27 |
20140086832 | DELIVERY SYSTEM FOR CYTOTOXIC DRUGS BY BISPECIFIC ANTIBODY PRETARGETING - The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties. | 2014-03-27 |
20140086833 | NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE - The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described. | 2014-03-27 |
20140086834 | NEW I-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF - The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition. | 2014-03-27 |
20140086835 | Methods and Compositions for Heptameric Targeting Ligands - The present invention provides a self assembly molecule having an affinity for one or more target molecules, for use in formation of a heptameric complex, comprising: a) a monomer comprising a multimerization domain of Archaeal Sm1 (AF-Sm1) protein or SM-like ribonucleoprotein from other organisms, able to interact with other molecules of the same monomer comprising a multimerization domain of AF-Sm1 protein or SM-like ribonucleoprotein to self-assemble into a heptamer; and b) a target binding domain or peptide attached directly or via a linker to the monomer of (a). Also provided are heptamers comprising these self assembly molecules and methods for their use in therapy, imaging and diagnostics. | 2014-03-27 |
20140086836 | METHOD FOR DETECTION OF A NEUROLOGICAL DISEASE - The present invention provides methods for predicting whether a subject will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the predictive detection of neurological diseases in a subject. The methods and systems provided enable a quantitative assessment and theoretical predictions of neocortical amyloid loading or amyloid beta levels based on the measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD). | 2014-03-27 |
20140086837 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION - The invention relates to | 2014-03-27 |
20140086838 | IDENTIFICATION OF A NEW MOLECULAR FACTOR FOR EARLY DIAGNOSIS OF UROTHELIAL CARCINOMA OF THE BLADDER - The identification is disclosed of a new molecular factor for the early diagnosis of urothelial carcinoma of the bladder. HtrA1 is a molecule that is produced mainly by the urothelium of the bladder, both in physiological and inflammatory pathologies, such as cystitis, whereas it is absent in the urothelial layer of the neoplastic bladder mucosa, regardless of cancer grade and level. By means of Western Blotting two forms of HtrA1 were identified, both in bladder tissue and urine, the native 50 kDa form and the autocatalytic 38 kDa form. The 38 kDa form is significantly underexpressed in tumoral tissues compared with normal tissues and concentration of the 50 kDa form in urine is significantly higher in patients affected by bladder cancer compared to healthy subjects and subjects with cystitis. Therefore, the evaluation of tissutal and urinary HtrA1 levels can be a specific marker of urothelial carcinoma of the bladder. | 2014-03-27 |
20140086839 | QUINOLONE ANALOGS FOR TREATING AUTOIMMUNE DISEASES - Provided are methods of treating autoimmune diseases by administering to the subject a therapeutically effective amount of a quinolone compound such as 2-(4-methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide (CX-5461). Also provided are methods of monitoring efficiency of treatment of the quinolone compound by determining the expression level of at least one gene of the RNA polymerase I pathway. | 2014-03-27 |
20140086840 | Therapeutic Antibody Target Validation and Screening In Vivo - An in vivo method of validating a candidate therapeutic target molecule is provided. An in vivo method of selecting a therapeutic antibody to a specific target molecule is also provided. | 2014-03-27 |
20140086841 | PIG FOR ATRIOVENTRICULAR BLOCK MODEL, MONKEY FOR ATRIOVENTRICULAR BLOCK MODEL, GUINEA PIG FOR ATRIOVENTRICULAR BLOCK MODEL, AND USE THEREOF - A method for allowing an animal to develop atrioventricular block, the method including: administering an immune regulator targeting a sphingosine-1-phosphate receptor to an animal selected from a pig, a monkey and a guinea pig. | 2014-03-27 |
20140086842 | SCREENING METHODS USING G-PROTEIN COUPLED RECEPTORS AND RELATED COMPOSITIONS - The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides. | 2014-03-27 |
20140086843 | BIFUNCTIONAL HYDROXY-BISPHOSPHONIC ACID DERIVATIVES - The present invention relates to a bifunctional hydroxy-bisphosphonic acid derivative of formula (I) below: | 2014-03-27 |
20140086844 | LUMINESCENT COMPOUNDS - Dyes and photoluminescent compounds based on polymethine dyes that contain at least one alkyl-phosphonate or substituted alkyl-phosphonate group, including the synthetic precursors, methods of synthesis, and applications thereof. Certain embodiments include heterocyclic ring systems and polymethine linkages selected such that the resulting polymethine dye is a cyanine dye, a merocyanine dye or a styryl dye. | 2014-03-27 |
20140086845 | METHOD FOR IMAGING A SITE OF ARTHRITIS IN AN ANIMAL - The present disclosure demonstrates that a nanovesicle comprising a membrane-associated lysosomal protein (saposin C; “SapC”) incorporated into a phospholipid has a high fusogenic affinity for phosphatidylserine-rich domains on the surfaces of target cell membranes. It is believed that the nanovesicles target surface exposed phosphatidylserine on the membranes of cells associated with arthritis, allowing for detection of local tissue damage associated with arthritis. In plasma membranes, phosphatidylserine is normally present only on the inner leaflet but is “flipped” to the outer leaflet upon the presence of cell damage. Incorporation of the fluorophore in the nanovesicles allows for the in vivo visualization of the fluorophore in targeted tissue and provides a technique to detect and evaluate the onset and progression of arthritic disease in an animal. Furthermore, the use of the nanovesicle in optical imaging methods provides great promise for analyzing events occurring early in the pathogenesis of arthritis and arthritic disease. | 2014-03-27 |
20140086846 | CONTRAST ENHANCEMENT AGENTS AND METHOD OF USE THEREOF - A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): | 2014-03-27 |
20140086847 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE - The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 2014-03-27 |
20140086848 | FOAMABLE COMPOSITIONS AND METHODS FOR DISORDERS OF THE SKIN OR MUCOSAL SURFACES - The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis. | 2014-03-27 |
20140086849 | Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof - The present invention relates to combination therapies for the treatment of a variety of disorders in mammals, including hepatic disorders and cancer. The combination of agents includes naturally-occurring (versus synthetic) oligonucleotides, particularly immunostimulatory oligodeoxynucleotides such as CpG ODNs, obtained from a natural source and one or more extracts from a Gram positive bacteria, such as | 2014-03-27 |
20140086850 | PHOSPHATE COMPOSITION FOR DENTAL STRENGTHENING - A dentition strengthening delivery system having separate phosphate and calcium salts derived from separate source in a semisolid comestible matrix. The ratio of phosphate to calcium is at least 1:1, and the phosphate concentration is between about 10 ppm to about 10,000 ppm. | 2014-03-27 |
20140086851 | Low Water Metal Ion Dentifrice - A dentifrice composition having a low water phase comprising effective amounts of polyphosphate and ionic active ingredients. The composition comprises a source of metal ions, an inorganic phosphate salt having four or more phosphorus atoms and a cross-linked polyvinylpyrrolidone thickening agent in a single phase. Preferred metal ions are stannous, copper and zinc, in particular from zinc citrate and stannous fluoride. | 2014-03-27 |
20140086852 | Personal Compositions With Silicone Emulsifier-Free Natural Emulsifier System - A personal care composition in the form of an oil-in-water emulsion comprising at least one sucrose fatty acid ester and at least one nonionic surfactant, said composition having a soaping index of less than about 2. The compositions are suitable for conditioning and moisturizing applications, and are optionally substantially free of silicone emulsifiers. | 2014-03-27 |
20140086853 | Personal Compositions With Silicone Emulsifier-Free Natural Emulsifier System - The present invention relates to a personal care composition comprising at least one sucrose fatty acid ester and at least one nonionic surfactant, wherein the composition is substantially free of silicone emulsifiers. The personal care compositions are particularly suitable for conditioning and moisturization applications. | 2014-03-27 |
20140086854 | Polymers Based On Sulfonic Acids, Amides And Special Cross-Linking Agents - The invention relates to water-soluble or water-swellable polymers that contain a) 20.0 to 98.97 mole-% of one or more repeating structural units originating from special monomers with sulfonic acid groups or the salts thereof such as e.g. 2-acrylamido-2-methyl-propanesulfonic acid or the salts thereof, b) 1.0 to 60.0 mole-% of one or more repeating structural units containing an amide group and d) 0.01 to 8.0 mole-% of one or more repeating structural units originating from special crosslinking agents with at least three polymerizable double bonds. The polymers for example have an advantageous sensory property profile and are highly suitable as thickening agents even in salt-containing compositions. They are furthermore advantageously suitable for producing cosmetic, dermatological or pharmaceutical compositions. | 2014-03-27 |
20140086855 | COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME - The present invention provides combined use of a carnosinase inhibitor with L-carnosine and its related substance, and a composition containing the same, which are useful for treatment or prevention of various diseases, improvement of health conditions, improvement of exercise ability, improvement of skin health, prevention of the side effects of alcohol drinking and the like in mammals including human. | 2014-03-27 |
20140086856 | SILICONE COMPOUND AND PHOTOPROTECTIVE PERSONAL CARE COMPOSITIONS COMPRISING THE SAME - The present invention relates to silicone compounds which have photoprotective properties and personal care compositions comprising the same. The present inventors, in developing a sunscreen that gives protection against both UV radiation and visible radiation, found that when a certain moiety generally occurring in nature i.e. hydroxyanthraquinone having uv-visible absorption activity are attached to crosslinked silicone polymers they provide not only the desired photoprotection but also excellent spreadability on skin. | 2014-03-27 |
20140086857 | Compositions Comprising Siloxane Polymer - Compositions comprising siloxane polymers are disclosed. The compositions are useful as thixotropic bases for a variety of components, such as antimicrobial agents, sterilants, medicaments, antibiotics, analgesics, essential oils, preservatives, colorants, fragrances, and the like. Methods for preparing the compositions are also disclosed. | 2014-03-27 |
20140086858 | BODY WASH WITH SUNSCREEN SYSTEM AND METHOD - A body wash composition includes sunscreen or UV screen materials. The body wash composition is formulated so that it may be applied during normal hygiene activities, such as washing. However, the composition applies an effective level of sunscreen or UV screen material to the body such that the sunscreen or UV screen continues to provide effective solar protection even after rinsing or washing of the human body. Further, the material is a non-greasy, easy to apply material that may be used during showering activities in a manner similar to using a bar soap or cleanser. The composition includes a variety of materials that assist in the processing and storage of the body wash. Effective amounts of solar protective material include octyl methoxycinnamate, octyl salicylate, and titanium dioxide. Testing shows that the product provides a solar protective level of at least approximately 14 even after multiple rinsings. Further embodiments have achieved a solar protective level of at least approximately 17. | 2014-03-27 |
20140086859 | LOW OIL COMPOSITIONS COMPRISING A 4-SUBSTITUTED RESORCINOL AND A HIGH CARBON CHAIN ESTER - A composition including water, about 0.1% to about 0.4% of a 4-substituted resorcinol, an ester having at least about 25 carbon atoms, and a polymeric emulsifier is provided. The composition comprises less than about 5% by weight of oils and is substantially free of monomeric emulsifier. Methods of treating the skin are also provided. | 2014-03-27 |
20140086860 | SKIN LIGHTENING COMPOSITION - The invention relates to a skin lightening composition, more particularly a composition which derives synergy between an active of natural origin and an active of synthetic origin. The present inventors have judiciously combined a selective salt of a dicarboxylic acid viz. disodium fumarate along with a specific extract of a plant source e.g. | 2014-03-27 |
20140086861 | HYDROPHILIC TREATED PIGMENTS DISPERSIBLE IN A COSMETIC COMPOSITION - The invention relates to a pigment composition comprising:
| 2014-03-27 |
20140086862 | COLORED RESIN PARTICLES, METHOD FOR PRODUCING THE SAME, AND USE THEREOF - The present invention provides colored resin particles having excellent adhesiveness, a method for producing the same, and use thereof. Each of the colored resin particles is surface-coated with a polymer derived from a nitrogen-containing aromatic compound, and has an irregular shape with a circular appearance when viewed from a direction in which a projected area thereof becomes maximum, and with a non-circular appearance when viewed from a direction in which the projected area thereof becomes minimum. | 2014-03-27 |
20140086863 | Cosmetic Composition - Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). | 2014-03-27 |
20140086864 | Shampoo Compostion - A shampoo composition excellent in fading-inhibiting effect and use feeling is provided. The shampoo composition is characterized by comprising:
| 2014-03-27 |
20140086865 | Antimicrobial Constructs - The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers. | 2014-03-27 |
20140086866 | Methods For Endoscopic Mucosal Resection And Endoscopic Submucosal Dissection - In one aspect, methods for separating biological tissue are described herein. In some embodiments, a method for separating tissue comprises providing a first composition comprising a polymerizable material, providing a second composition comprising a polymerization initiator, disposing the first composition at a first site beneath a first tissue layer, disposing the second composition at the first site, polymerizing the polymerizable material at the first site, and separating the first tissue layer from a second tissue layer. | 2014-03-27 |
20140086867 | Systems, Compositions and Methods for the Treatment of Alopecia - A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target location on the scalp of the subject to induce an inciting event at the target scalp location, and (iii) administering a therapeutically effective amount of said ECM composition to the target scalp location. In some embodiments, the ECM composition includes at least one additional biologically active agent. | 2014-03-27 |
20140086868 | USE OF IL-17D FOR THE TREATMENT AND PREVENTION OF CANCERS - The present invention relates to the treatment and prevention of cancers, particularly cancers whose growth is reduced or inhibited by immunostimulatory therapy, by the administration of interleukin-17D (IL-17D), compounds that can increase the production, half-life, or activity of IL-17D, or compositions that contain IL-17D. | 2014-03-27 |
20140086869 | METHODS AND COMPOSITIONS FOR TREATING TUMORS USING MYELOID DERIVED SUPPRESSOR CELLS - Compositions and methods for diagnosing and treating tumors using myeloid derived suppressor cells (MDSCs) are provided. More particularly, the compositions contain labeled MDSCs or MDSCs in combination with oncolytic viruses, nano-particles or other anti-tumor agents. | 2014-03-27 |
20140086870 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS - New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). | 2014-03-27 |
20140086871 | ULTRALONG COMPLEMENTARITY DETERMINING REGIONS AND USES THEREOF - Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject. | 2014-03-27 |
20140086872 | Methods of Treating a Subject for a Condition - Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods. | 2014-03-27 |
20140086873 | Esters and Malonates of SATE Prodrugs - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula 1001: | 2014-03-27 |
20140086874 | BIOMATERIAL, METHOD FOR MAKING THE BIOMATERIAL AND USES OF THE SAME - A method for making a biomaterial comprising providing at least one polypeptide fraction chymotryptically isolated and extracted from fibroin, and adding the at least one extracted polypeptide fraction to a hydrogel precursor before gelling, wherein the at least one isolated and extracted polypeptide fraction is selected from a soluble fraction Cs, and a precipitated fraction Cp. A biomaterial comprising at least one of the isolated and extracted polypeptide fractions incorporated in a hydrogel or a hydrogel precursor. Use of the biomaterial for constructing, regenerating, repairing, replacing or augmenting soft or hard tissue; as an in vitro or in vivo construct; as a coating material; or as a cell, molecule or particle delivery medium. Use of the isolated and extracted polypeptide fraction Cs for promoting osteoinduction, osteoconduction or osteogenesis. Use of the isolated and extracted polypeptide fraction Cp for enhancing a mechanical compressive modulus of a material into which it is incorporated. | 2014-03-27 |
20140086875 | COMPOSITION BASED ON BACILLUS SPP. AND CORRELATE GENERA AND THEIR USE IN PEST CONTROL - The objective of the current invention is the control of agricultural infestations based on alternative methods that are less aggressive to the environment and that are harmless to other invertebrates and to man; for instance biological control using bacterial strains belonging to species of the genera | 2014-03-27 |
20140086876 | BIOCONTROL COMPOSITIONS - The invention provides isolated | 2014-03-27 |
20140086877 | BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS - This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota. | 2014-03-27 |
20140086878 | Muscodor albus Strain Producing Volatile Organic Compounds and Methods of Use - Disclosed herein is an isolated | 2014-03-27 |
20140086879 | Muscodor Albus Strain Producing Volatile Organic Compounds and Methods of Use - Disclosed herein is an isolated | 2014-03-27 |
20140086880 | METHOD FOR TREATING NEURODEGENERATIVE TAUOPATHY - The present invention is directed to a filamentous bacteriophage for use in treating a neurodegenerative tauopathy or susceptibility to a neurodegenerative tauopathy and a method of using the bacteriophage for reducing the formation of fibrils of tau protein or for disaggregating pre-formed fibrils of tau protein, such as in a patient suffering from neurodegenerative tauopathy. The filamentous bacteriophage used in the present invention does not display (i) a mammalian cell internalization signal (ii) a β-amyloid antigen or an antibody to β-amyloid, or (iii) a tau protein antigen or an antibody to tau protein. | 2014-03-27 |
20140086881 | GOOD HEALTHY CELLS FOUND IN PROTEINS, THEIR APPLICATIONS, AND PROCESS OF MAKING A MEDIUM TO HARVEST THE CELLS - GOOD HEALTHY DRAGON, SNAKE, DIFFERENT SIZE DOUBLE RINGS, LIGHTNING, SQUARE PIXEL, BEAMING RAYS, RECONSTRUCTION BACKGROUND, FACET, CRATER, YELLOW, LEER CELLS were found in New Proteins (among them 27 new ones and their sequences (Under a different patent application) or in the existing discovered proteins and their applications. The process of making the medium derived from any source to harvest any cell—named KH cells—KH cells are good healthy cells in which the RNA synthesizes good proteins that: 1—Send signal to the DAMAGED, SICK, AND BAD CELLS that triggers that synthesis of good proteins that transform these cells to become GOOD healthy cells. 2—Send signal to the other currently undamaged cells to synthesis of good proteins to protect them from being DAMAGED, INFECTED and PRONE to DNA and other cellular alterations. 3—Send signal to the body to produce new cells that are healthy and forbid them from being affected by intra- and extracellular damaging signals to increase the protein yield for the application of the cell expression of human healthcare, animal healthcare and plant healthcare including fertilizer and maximize production of medicine, food, fruit, juice, meat, seafood and plants. | 2014-03-27 |
20140086882 | STEM CELL PREPARATIONS AND METHODS OF USE - The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. The invention has been developed primarily as a method for preparing and culturing BSC. | 2014-03-27 |
20140086883 | Compositions and Methods for the Generation of Platelets and Methods of Use Thereof - Compositions and methods for generating platelets and methods of use thereof are disclosed. | 2014-03-27 |
20140086884 | TREATMENT OF DISEASES AND DISORDERS USING SELF-RENEWING COLONY FORMING CELLS CULTURED AND EXPANDED IN VITRO - The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 2014-03-27 |
20140086885 | METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION - Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins. | 2014-03-27 |
20140086886 | Stem Cell, Precursor Cell, or Target Cell-Based Treatment of Multi-Organ Failure and Renal Dysfunction - Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof. | 2014-03-27 |
20140086887 | ADULT STEM CELL LINE INTRODUCED WITH HEPATOCYTE GROWTH FACTOR GENE AND NEUROGENIC TRANSCRIPTION FACTOR GENE WITH BASIC HELIX-LOOP-HELIX MOTIF AND USES THEREOF - The present invention relates to an adult stem cell line introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, a preparation method of the adult stem cell line, a composition for the prevention or treatment of neurological diseases comprising the adult stem cell line, and a method for treating neurological diseases comprising the step of administering the composition to a subject having neurological diseases or suspected of having neurological diseases. The adult stem cells according to the present invention, which are introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, can be used to overcome chronic impairment caused by cell death following stroke. Thus, the adult stem cells can be developed as a novel therapeutic agent or widely used in clinical trial and research for cell replacement therapy and gene therapy that are applicable to neurological diseases including Parkinson's disease, Alzheimer disease, and spinal cord injury as well as stroke. | 2014-03-27 |
20140086888 | EBV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF LOCOREGIONAL NASOPHARYNGEAL CARCINOMA (NPC) - The present invention concerns methods and compositions for treatment of locoregional nasopharyngeal carcinoma utilizing EBV-specific T cells. In specific embodiments, locoregional solid tumors are treated with cytotoxic T lymphocytes specific for at least one EBV antigen, such as LMP2, LMP1, and/or EBNA1, for example. | 2014-03-27 |
20140086889 | METHOD FOR EXPANDING CD4+CD25+T REGULATOR CELLS - A method for generating/expanding in vitro a CD4 | 2014-03-27 |
20140086890 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS - This invention generally relates to a composition comprising an enriched NK cell population. The invention further relates to a method of treating a solid tumor or a hyperproliferative disorder by administering the enriched NK cell population to a mammalian subject in need thereof. | 2014-03-27 |
20140086891 | COMPOSITIONS AND METHODS FOR PROMOTING TISSUE REGENERATION - Provided are compositions for promoting bone and cartilage growth. In certain embodiments, tissue graft compositions comprising a polymeric scaffold (e.g., PLGA), hyaluronic acid, and substantially purified mononucleated cells derived from bone marrow aspirate. In various embodiments, the tissue graft composition may comprise thrombin. The tissue grafts may be used to promote bone growth, e.g., in a spinal fusion operation. | 2014-03-27 |
20140086892 | RED BLOOD CELL PRODUCTS AND THE STORAGE OF RED BLOOD CELLS IN NON-PVC CONTAINERS - Red blood cell products are disclosed. The product includes a container made from a non-PVC, substantially plasticizer-free material. The product includes a RBC concentrate and a hypotonic solution for storing the RBCs. | 2014-03-27 |
20140086893 | Regimen For Reducing The Appearance Of Thinning Hair - A method for reducing the appearance of thinning hair comprising the successive steps of: a) treating hair with an exfoliating shampoo composition comprising at least one chemical exfoliant; b) treating hair with a conditioner comprising at least one natural conditioning polymer and at least one natural stimulant; c) treating hair with a scalp serum comprising at least one natural extract, and salicylic acid. | 2014-03-27 |
20140086894 | Novel Compositions and Uses Thereof - Compositions and their use in the treatment or prevention of hyperglycemia and related diseases or disorders are disclosed. | 2014-03-27 |
20140086895 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune diseases, especially rheumatoid arthritis. More particularly, the present invention relates to an a-enolase polypeptide for use in the prophylactic treatment of an autoimmune disease in a subject in need thereof. | 2014-03-27 |
20140086896 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders - The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease. | 2014-03-27 |
20140086897 | CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF - Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | 2014-03-27 |
20140086898 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 2014-03-27 |
20140086899 | DIAGNOSTIC AND PROGNOSTIC ASSAY FOR A CONDITION OR EVENT OF THE VASCULAR SYSTEM - The present disclosure relates generally to the field of diagnostic and prognostic assays for a condition or event of a vascular system such as the cerebrovascular system. An assay is taught herein for monitoring progression of a condition or event of a vascular system such as the cerebrovascular system as well as determining the state or stage of the condition or event. The assay of the present disclosure is also useful in the stratification of a subject based on the stage or development of the condition or event. | 2014-03-27 |
20140086900 | Lyophilized Preparation of Botulinum Toxin - There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed. | 2014-03-27 |
20140086901 | Inhibition of Post-Radiation Tumor Growth - Compositions and methods for inhibiting the growth of solid tumors following radiation treatment are described. The compositions and methods target matrix metalloproteinases and bone marrow-derived cells expressing matrix metalloproteinases. | 2014-03-27 |
20140086902 | DETERMINING IMMUNOGLOBULINS IN NON-BLOOD BODY FLUIDS OF NEONATAL UNGULATES - Provided is a method for determining immunoglobulins in a neonatal ungulate. The method entails obtaining a sample of oral secretions from the neonatal ungulate and measuring an amount of immunoglobulins in the sample of oral secretions. The method is faster and more convenient than previously available methods for determining immunglobulins in neonatal ungulates, such as neonatal horses and cattle. | 2014-03-27 |
20140086903 | CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF - The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases. | 2014-03-27 |
20140086904 | Humanized Anti-TNF-alpha Antibody and Antigen-Binding Fragment (Fab) Thereof and Use of the Same - The present invention discloses a humanized anti-human tumor necrosis factor-α antibody and antigen-binding fragment (Fab) thereof. The present invention also discloses a composition comprising the said antibody or antigen-binding fragment (Fab) thereof, and the use of the said antibody or antigen-binding fragment (Fab) thereof in treating the diseases associated with tumor necrosis factor-α. | 2014-03-27 |
20140086905 | IMMUNOLOGICAL COMPOSITIONS AS CANCER THERAPEUTICS - The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves. | 2014-03-27 |
20140086906 | Optimized Antibodies That Target CD19 - The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcgγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention. | 2014-03-27 |